ABBV vs BRK.B Stock Comparison: Price, Growth & Valuation (2026)
Use MEXC Stock Compare for a detailed ABBV vs BRK.B analysis. Compare ABBV and BRK.B across price performance, growth, valuation, profitability and risk, based on market data and the latest reported financials.
ABBV vs BRK.B Stock Comparison Summary
ABBV reported year-over-year revenue growth of 10.4%, compared with 4.0% for BRK.B. Their P/E ratios are 74.5x and 12.6x, dividend yields are 2.56% and 0.00%, and 30-day volatility levels are 20.1% and 13.7%, respectively. These metrics highlight key differences in growth, valuation, dividend income and market risk. Overall neither stock has a clear lead based on the selected metrics.
Risk Disclaimer: MEXC Stock Compare provides information and comparisons on actual U.S.-listed stocks for reference only. Data may be delayed or inaccurate, does not constitute investment advice, and past performance does not guarantee future results.
ABBV vs BRK.B Stock Return Comparison (1W)
Compare the cumulative total returns of ABBVIE INC. (ABBV) and BERKSHIRE HATHAWAY (BRK.B) over the selected 1W period. Data as of 2026-09-25 12:00:00.
ABBV vs BRK.B Key Equity Metrics Comparison Summary
ABBVIE INC. (ABBV) has a market capitalization of $466.93B and operates in the Health Care sector, with its main business classified under Biotechnology. Its latest quarterly revenue changed +10.4% year over year.
BERKSHIRE HATHAWAY (BRK.B) has a market capitalization of $712.18B and operates in the Financials sector, with its main business classified under Multi-Sector Holdings. Its latest quarterly revenue changed +4.0% year over year.
ABBV vs BRK.B Key Stock Indicators
| Comparison Metric | ABBV | BERKSHIRE HATHAWAY BRK.B | Comparison results |
Stock Price & Returns Latest delayed stock price with 1-day, 1-month and year-to-date returns. | $264.281D: -0.3%1M: +2.4%1Y: +20.9% | $505.801D: +0.1%1M: +0.4%1Y: +2.2% | ABBVWin |
Market Capitalization Total market value of the company's outstanding shares. | $466.93B | $712.18B | BRK.BWin |
Sector & Industry The company's market sector and primary industry classification. | Health Care / Biotechnology | Financials / Multi-Sector Holdings | -- |
| Based on delayed market data, ABBV is trading at $264.28, compared with $505.80 for BRK.B. Their market capitalizations are $466.93B and $712.18B, respectively. ABBV operates in the Health Care sector, while BRK.B belongs to Financials. | |||
| ABBV vs BRK.B Growth & Profitability | |||
Revenue Growth (YoY) Year-over-year change in revenue. | +10.4% | +4.0% | ABBVWin |
EPS Growth (YoY) Year-over-year change in earnings per share. | +68.6% | +36.3% | ABBVWin |
ROIC Return generated from invested capital. | 22.3% | 3.1% | ABBVWin |
Gross Margin / Operating Margin Profitability before and after operating expenses. | 71.5% / 25.9% | 44.5% / 9.0% | ABBVWin |
| On growth, ABBV posted revenue growth of +10.4% and TTM EPS growth of +68.6%. BRK.B, by comparison, posted revenue growth of +4.0% and TTM EPS growth of +36.3%.On profitability, ABBV recorded a gross margin of 71.5%, an operating margin of 25.9%, and ROIC of 22.3%. For BRK.B, the corresponding figures were 44.5%, 9.0%, and 3.1%.Overall, ABBV shows stronger overall growth and profitability. | |||
| ABBV vs BRK.B Valuation & Balance Sheet | |||
Free Cash Flow Yield Free cash flow as a percentage of market capitalization. | 3.9% | 2.2% | ABBVWin |
Net Debt / EBITDA Net debt relative to EBITDA; a negative value indicates net cash. | 2.1x | 1.7x | BRK.BWin |
Dividend Yield / Payout Ratio Dividend returns relative to share price and the share of earnings paid as dividends. | 2.56% / 190.1% | 0.00% / 0.0% | ABBVWin |
| ABBV offers a higher free cash flow yield, indicating a less demanding valuation. BRK.B has the stronger balance sheet, while ABBV provides the higher dividend yield. Overall, the two stocks differ mainly in valuation, financial strength and dividend income. | |||
| ABBV vs BRK.B Returns & Risk | |||
Total Return (Dividend-Adjusted) Cumulative return over 1, 5 and 10 years, including dividends. | 1Y: +20.9%5Y: +145.3%10Y: +312.5% | 1Y: +2.2%5Y: +80.8%10Y: +250.8% | ABBVWin |
30-Day Realized Volatility Annualized volatility based on the past 30 days of daily returns. | 20.1% | 13.7% | BRK.BWin |
Beta (5Y vs S&P 500) Sensitivity to market movements; above 1 indicates greater market volatility. | 0.29 | 0.58 | ABBVWin |
| ABBV has delivered stronger long-term returns, but the risk indicators show mixed results. | |||
ABBV vs BRK.B Valuation & Dividend Metrics
Review ABBV compared with BRK.B across valuation, cash flow and dividend metrics, including P/E, forward P/E, free cash flow yield and dividend yield. These figures are provided for reference only and do not represent a fair-value estimate, price target or investment recommendation.
| Metric | ABBV | BERKSHIRE HATHAWAY BRK.B | Comparison results |
|---|---|---|---|
Market Cap | $466.93B | $712.18B | BRK.BWin |
P/E (TTM) | 74.5x | 12.6x | BRK.BWin |
P/S | 7.3x | 3.1x | BRK.BWin |
EV/EBITDA | 18.1x | 25.7x | ABBVWin |
Dividend Yield | 2.56% | 0.00% | ABBVWin |
ABBV vs BRK.B Profitability Over Time
Compare ABBV and BRK.B across gross margin and operating margin trends over time to understand how each company's profitability has changed. Based on reported financial data only; not a forecast or investment advice.
| TTM | 3Y Avg | 5Y Avg | 10Y Avg | |
|---|---|---|---|---|
| ABBV | 70.2% | 67.5% | 68.3% | 71.4% |
| BRK.B | 47.0% | 45.9% | 47.7% | 45.9% |
Technical & Fundamental Stock Analysis
RSI (14, daily)
ABBV 58.52 • BRK.B 48.45
Measures short-term price momentum and helps identify possible overbought or oversold conditions.
50/200-DMA Position
ABBV 50D Above / 200D Above • BRK.B 50D Below / 200D Above
Shows whether the stock is trading above or below its medium- and long-term trend lines.
R&D % of Revenue
ABBV 15.1% • BRK.B 0.0%
Shows how much of revenue is invested in research and development.
Share Count Trend (3Y)
ABBV Stable • BRK.B Stable
Shows whether the company's share count has increased or decreased over the past three years.
Company Profiles
ABBVIE INC.
Biotechnology
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
BERKSHIRE HATHAWAY
Multi-Sector Holdings
Berkshire Hathaway is a holding company with a wide array of subsidiaries engaged in diverse activities. The firm's core business segment is insurance, run primarily through Geico, Berkshire Hathaway Reinsurance Group, and Berkshire Hathaway Primary Group. Berkshire has used the excess cash thrown off from its operations to acquire Burlington Northern Santa Fe (railroad), Berkshire Hathaway Energy (utilities and energy distributors), and the companies that make up its manufacturing, service, and retailing operations (which include Precision Castparts, Lubrizol, Clayton Homes, Marmon, and IMC/ISCAR). The conglomerate is unique in that it is run on a completely decentralized basis. Berkshire generated close to $371.4 billion in operating revenue in during 2025.
Trade ABBV & BRK.B Stock Futures on MEXC
Trade USDT-margined Stock Futures referencing ABBV and BRK.B on MEXC, with 24/7 access and leverage of up to 10x. These products are derivatives, do not represent ownership of the underlying shares and involve a significant risk of loss.
Everything You Need to Know About ABBV vs BRK.B Stocks
What is MEXC Stock Compare?
MEXC Stock Compare is a side-by-side US stock comparison tool. It helps users compare two companies across stock price performance, market cap, valuation, growth, profitability, balance-sheet strength, dividends and risk. The results are provided for research purposes only and do not constitute investment advice.
Which metrics should I use to evaluate a company's growth?
Start with revenue growth to see how quickly the business is expanding, then review EPS growth to determine whether that growth is translating into higher earnings per share. Gross margin, operating margin and ROIC help assess the quality of that growth by showing profitability and capital efficiency. A company with fast revenue growth but declining margins may be expanding without improving its earnings quality.
How do ABBV and BRK.B compare in growth and profitability?
In the latest reported period, ABBV recorded revenue growth of +10.4% and TTM EPS growth of +68.6%, compared with +4.0% and +36.3% for BRK.B. ABBV leads on both growth and profitability. This comparison is based on reported financial metrics and does not predict future performance.
What is the difference between P/E (TTM) and Forward P/E?
P/E (TTM) compares the current share price with actual earnings reported over the past 12 months. Forward P/E uses estimated earnings for the next 12 months, so it reflects market expectations but depends on forecasts that may change. Both ratios should be considered alongside growth, profitability and industry peers.
How do the risk profiles of ABBV and BRK.B compare?
ABBV has a 30-day realized volatility of 20.1% and a five-year Beta of 0.29, compared with 13.7% and 0.58 for BRK.B. The risk indicators show mixed results. These indicators describe historical price movements and market sensitivity, but they do not cover every source of investment risk.
What do dividend yield and payout ratio indicate?
Dividend yield shows the annual dividend relative to the current share price, while the payout ratio shows how much of a company's earnings is distributed as dividends. A higher yield may provide more income, but it can also rise because the share price has fallen. Dividend sustainability should therefore be considered together with earnings, cash flow and the payout ratio.
How should I compare a high-growth stock with a lower-valued stock?
A high-growth stock may trade at a higher valuation if investors expect its revenue and earnings to continue expanding. A lower-valued stock may offer a more conservative entry point, but the lower valuation could also reflect slower growth or higher business risk. Growth, valuation, profitability, cash flow and risk should therefore be considered together.
Which is the better stock, ABBV or BRK.B?
There is no single answer for every investor. Growth-focused investors may place greater weight on revenue growth, EPS growth and ROIC, while income-focused investors may prioritize dividend yield and payout sustainability. Investors with lower risk tolerance may focus more on volatility, Beta and balance-sheet strength. MEXC Stock Compare presents the relevant metrics but does not provide a buy or sell recommendation.
Can I trade ABBV and BRK.B as RealStocks on MEXC?
Eligible users can trade ABBV and BRK.B as real US stocks through MEXC RealStocks if both stocks are currently supported. Users must first open and verify a RealStocks account with MEXC's partner licensed broker. RealStocks represents ownership of actual shares rather than tokenized stock exposure. Availability may vary by stock and region, so users should check the corresponding RealStocks trading page before placing an order.
Disclaimer
The stock prices, financial metrics, comparison results and related information displayed on this page are sourced from third-party providers and are provided for informational and educational purposes only. Data may be delayed, incomplete or inaccurate, and MEXC does not guarantee its accuracy, completeness or timeliness. The comparisons and automated summaries do not constitute financial, investment, legal or tax advice, nor a recommendation to buy, sell or hold any security or financial product. Past performance is not indicative of future results. Users should independently verify the information and assess their own objectives, financial circumstances and risk tolerance before making any decision. Where MEXC stock futures or other derivative products are referenced, such products do not represent ownership of the underlying shares and may involve leverage and a substantial risk of loss. Product availability is subject to applicable laws and regional restrictions.